Phenomex v. University of British Columbia: Federal Circuit Affirms Microfluidic Patent Ruling
Phenomex, Inc. challenged the University of British Columbia over US10087408B2, covering systems and methods for microfluidic cell culture. After 650 days of appellate proceedings, the Federal Circuit affirmed the lower tribunal’s patentability determination, leaving UBC’s patent position intact.
Federal Circuit closes Phenomex’s microfluidic patent challenge against UBC
Phenomex, Inc. — a life-science tools company active in microfluidics and single-cell analysis — filed an appeal at the United States Court of Appeals for the Federal Circuit on 1 August 2023, designated Case No. 23-2227. The appeal targeted a patentability determination relating to US10087408B2, a patent held by the University of British Columbia (UBC) that covers systems and methods for microfluidic cell culture. The underlying dispute centred on an invalidity or cancellation action in which the validity of UBC’s patent claims was formally contested.
The Federal Circuit issued its decision on 12 May 2025, affirming the ruling below. An affirmance at this level means the appellate court found no reversible legal error in the lower tribunal’s analysis of patentability. The basis of termination is recorded as ‘Appeal Dismissed,’ which, in Federal Circuit practice, is consistent with an affirmance that closes out the appeal without remand. For UBC, the outcome confirms the patent survived the invalidity or cancellation challenge. For Phenomex, it exhausts the appellate avenue pursued in this proceeding.
A duration of 650 days from filing to resolution is consistent with the Federal Circuit’s typical appellate timeline for contested patentability matters, which often run 18–24 months when full briefing and oral argument are involved. The public record does not disclose the precise claim-by-claim findings of the lower tribunal, the specific grounds of invalidity raised by Phenomex, or whether any claims were narrowed during the proceedings. What the record does confirm is that UBC’s patent emerges from this appeal with its validity upheld at every reviewed level.
Filing to Appeal Dismissed in 650 days
650 days from filing to Federal Circuit decision — longer than the median Federal Circuit appeal
Federal Circuit affirms: what the ruling means for both parties
Affirmance means the lower decision survives intact
When the Federal Circuit affirms, it holds that the lower tribunal committed no reversible error in its legal reasoning or factual findings. The challenged decision — here, a patentability determination on US10087408B2 — stands as issued. No remand was ordered, closing this appellate chapter entirely. The appellate court applies de novo review to legal questions such as claim construction and substantial evidence review to underlying factual findings on patentability.
No reversible error foundUBC’s microfluidic patent survives the invalidity challenge
For the University of British Columbia, affirmance is a meaningful enforcement win. US10087408B2 has now withstood a formal invalidity or cancellation action and subsequent Federal Circuit review. That procedural history strengthens the patent’s presumption of validity in any future infringement proceeding. Licensees and potential challengers will face a higher evidentiary bar, knowing the claims have already been scrutinised at appellate level.
Patent validity confirmed on appealPhenomex’s appellate route is now exhausted at this level
With the Federal Circuit affirming, Phenomex has no further avenue within this proceeding. A petition for rehearing en banc or a certiorari petition to the Supreme Court would be extraordinary next steps with low statistical success rates. Practically, this means US10087408B2 remains a live IP risk for any Phenomex product or platform that practices the claimed microfluidic cell culture methods. The company may need to reassess its design-around or licensing strategy.
Appellate options exhausted hereStrengthened UBC patent raises the bar for microfluidics competitors
An affirmed patent that has survived an invalidity challenge carries increased deterrent value across the microfluidics and cell culture sector. Competitors developing systems and methods in this space — particularly those building on microfluidic cell culture platforms — should treat US10087408B2 as a hardened IP asset. The ruling suggests UBC’s claims were sufficiently well-grounded to withstand Federal Circuit scrutiny, making design-arounds or new IPR petitions more strategically costly to pursue.
Higher bar for future IPR or challengeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Phenomex, Inc. | Company | Life-science tools and microfluidics company — challenger of US10087408B2Search in Eureka ↗ |
| Defendant | The University of British Columbia | Individual | Research university and patent holder of microfluidic cell culture IP (US10087408B2)Search in Eureka ↗ |
| Plaintiff counsel | Marc David Peters | Attorney | Counsel for Phenomex, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Turner Boyd LLP | Law Firm | Representing Phenomex, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Zeilberger | Attorney | Counsel for The University of British ColumbiaSearch in Eureka ↗ |
| Defendant counsel | Eric William Dittmann | Attorney | Counsel for The University of British ColumbiaSearch in Eureka ↗ |
| Defendant counsel | Max H. Yusem | Attorney | Counsel for The University of British ColumbiaSearch in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for The University of British ColumbiaSearch in Eureka ↗ |
| Defendant counsel | Rudolph Kim | Attorney | Counsel for The University of British ColumbiaSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing The University of British ColumbiaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s single-word verdict — AFFIRMED — carries precise legal weight in patentability appeals. It signals that the appellate panel, applying de novo review to questions of law and substantial evidence review to underlying facts, found no basis to disturb the lower tribunal’s analysis of US10087408B2’s patentability. The absence of a remand instruction indicates the panel saw no unresolved issues requiring further factual development. For UBC, this is the strongest possible appellate outcome; for Phenomex, it forecloses re-litigation of the grounds already raised.
US10087408B2 — System and Method for Microfluidic Cell Culture
US10087408B2, filed under application number US13/178395 and assigned to the University of British Columbia, protects systems and methods for microfluidic cell culture. Microfluidic cell culture technology enables precise manipulation of cells and growth media at sub-millimetre scales, enabling high-throughput screening, organoid culture, and controlled micro-environment experiments. The patent’s B2 designation indicates it issued after examination with at least one published amendment, suggesting the claims were substantively reviewed before grant.
Strategically, US10087408B2 sits at the intersection of academic research tools and commercially valuable life-science instrumentation. As pharmaceutical and biotech companies increasingly adopt microfluidic platforms for drug discovery, organ-on-chip models, and single-cell genomics workflows, university-held foundational patents in this space can command significant licensing revenue. The Federal Circuit’s affirmance strengthens UBC’s hand in any future licensing programme or enforcement campaign targeting commercial microfluidics vendors, including those in the high-throughput cell culture instrument market.
Should your team run an FTO against US10087408B2?
Any company developing or commercialising microfluidic cell culture systems — including organ-on-chip platforms, closed-loop perfusion devices, droplet microfluidics for cell encapsulation, or automated cell culture workstations — should assess exposure to US10087408B2 as a priority. The patent has now survived appellate scrutiny, meaning a court is unlikely to find it invalid on the grounds previously raised. R&D teams launching new microfluidic culture products without a current FTO analysis are carrying unquantified IP risk.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US10087408B2 against your product architecture, flag prior art that remains unexhausted, and identify continuation or family members that may extend coverage. Eureka’s patent landscape view surfaces competing filings from both UBC and Phenomex, helping you understand where the white space lies and which design modifications are most likely to achieve non-infringement. Start with a targeted claim chart before your next product development milestone.
Run a freedom-to-operate analysis on US10087408B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patentability appeals in microfluidics and cell biology
Cases involving patentability challenges to microfluidic and cell culture technology at the Federal Circuit — comparable in procedural posture and technology domain to Case 23-2227.
What this case signals for the microfluidics and cell culture IP landscape
The Federal Circuit’s affirmance in Phenomex v. UBC has concrete implications for IP strategy in microfluidic cell culture technology.
Affirmed university patents carry amplified enforcement leverage
University-held patents that survive inter partes or cancellation review and a Federal Circuit affirmance command greater respect in licensing negotiations. UBC can now point to Federal Circuit endorsement when approaching potential licensees in the microfluidics sector. Companies receiving demand letters referencing US10087408B2 should model settlement economics against the elevated cost of another validity challenge.
Microfluidic cell culture platform developers face a tighter FTO window
Any R&D team developing closed-loop or high-throughput microfluidic cell culture systems should treat US10087408B2 as a priority FTO target. The claims have now been tested at appeal level. If your product workflow overlaps with the patented method, a design-around analysis conducted before product launch is substantially cheaper than litigation-stage licensing negotiations.
Phenomex v University — key questions answered
The Federal Circuit affirmed the lower tribunal’s patentability determination concerning US10087408B2, a University of British Columbia patent covering systems and methods for microfluidic cell culture. The decision, issued 12 May 2025, found no reversible error in the ruling below and closed the appeal without remand.
US10087408B2 is a patent granted to the University of British Columbia, filed under application US13/178395. It covers a system and method for microfluidic cell culture — technology that enables precise, small-scale manipulation of cells and culture media for applications such as drug discovery, organoid research, and high-throughput biological screening.
Affirmance means US10087408B2 has survived both a formal invalidity or cancellation challenge and subsequent Federal Circuit review. This procedural history strengthens the patent’s presumption of validity, making future invalidity challenges — including new IPR petitions on previously raised grounds — more difficult and costly for potential challengers.
Phenomex could theoretically petition for rehearing en banc at the Federal Circuit or seek certiorari at the Supreme Court, but both routes have very low success rates. Additionally, any invalidity grounds already raised in the prior proceeding are likely subject to estoppel, narrowing the grounds available in any future challenge or defence.
Phenomex was represented by Marc David Peters of Turner Boyd LLP. The University of British Columbia was represented by a team from Paul Hastings, LLP, including Daniel Zeilberger, Eric William Dittmann, Max H. Yusem, Naveen Modi, and Rudolph Kim.
PatSnap Eureka searches patents and litigation data to answer instantly.